Supportive Care for Patients With Hematological Malignancies Undergoing Hematopoietic Cell Transplant

PRIMARY OBJECTIVES:

I. Pilot a supportive care intervention that begins prior to transplantation and continues
through the acute peritransplant period.

II. Determine the proportion of patients who enroll and the level of comfort / distress of
hematopoietic cell transplant (HCT) patients who meet with the supportive care team.

III. Pilot data collection mechanisms and cost retrieval in preparation for a randomized
clinical trial.

OUTLINE:

Patients undergo supportive care consultation before transplantation and at least once
monthly while they remain at the transplant center.

Inclusion Criteria:

- Written informed consent

- English as primary language

- Planned autologous or allogeneic hematopoietic cell transplantation

- Presence of co-morbidities (hematopoietic cell transplant co-morbidity index [HCT-CI]
score 3 or greater), high risk disease (relapse risk > 25%), or a planned type of
transplant (human leukocyte antigen [HLA]-mismatched allogeneic or myeloablative)
that places the patient at a higher than average risk of non-relapse mortality or
relapse

Exclusion Criteria:

- Major psychiatric diagnosis that impairs cognitive functioning or is not controlled
at the time of the approach, as judged by the patient's medical team

- First transplant of a planned tandem procedure (the second transplant is eligible)